Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

MRC and Wellcome Trust Invest £24m in Cambridge Obesity Institute

Published: Thursday, May 30, 2013
Last Updated: Thursday, May 30, 2013
Bookmark and Share
The joint venture provides a unique environment linking basic and applied science in metabolic diseases.

The Institute houses not only state-of-the-art facilities for laboratory science, clinical and population research, but also purpose-built clinics providing out-patient care for children and adults with metabolic and endocrine disorders.

This close link to patients ensures that advances in basic science can be applied rapidly to improving patient care and disease prevention. The IMS is also close to the largest concentration of biotechnology companies in Europe, creating excellent opportunities for industrial collaboration.

Funding from the MRC will establish a new MRC Metabolic Diseases Unit (MDU) at the IMS, under the direction of Professor O’Rahilly, as well as new programmes of research at the existing MRC Epidemiology Unit and MRC Human Nutrition Research. The Wellcome Trust investment will create an enhanced Clinical Research Facility dedicated to metabolic studies, as well as providing funding for major core laboratory equipment and studies in animal models.

Stephen O’Rahilly, Co-Director of the Wellcome Trust-MRC IMS and Director of the MRC MDU, University of Cambridge, said:

“This joint initiative from the MRC and Wellcome Trust will provide exciting new opportunities to better understand the fundamental causes of disease such as obesity and diabetes and translate that knowledge into improved therapies.”

Professor Sir John Savill, Chief Executive of the MRC, said:

“Obesity is one of the biggest challenges facing the future health of the developed world and understanding the causes and consequences of this condition are major research priority. The MRC is very happy to be partnering with the Wellcome Trust and University of Cambridge in an ambitious joint venture that will unite experts in basic science, population science and experimental medicine to create a world-leading centre for metabolic research.”

Dr Ted Bianco, Acting Director of the Wellcome Trust, said:

“With obesity rates soaring across the globe, the need to understand the biological, behavioural and environmental factors that influence metabolic diseases has never been greater. This additional investment from us and the MRC reflects the quality of research that is being undertaken at Cambridge and lays the foundations for taking basic scientific discoveries right through to clinical advances.”

Professor Sir Leszek Borysiewicz, Vice-Chancellor of the University of Cambridge, said:
“Obesity has become an urgent public health issue as research continues to reveal its detrimental effects. With obesity doubling between 1980 and 2008 – a span of less than 30 years – investing in obesity research has never been more critical, and the University is delighted with the support of the MRC and the Wellcome Trust.”

The £24m joint investment will be broken down as follows:

o    £10.8m from the MRC to establish a new university unit: the MRC Metabolic Diseases Unit, University of Cambridge (Directed by Professor Steve O’Rahilly and located at the Wellcome Trust-MRC IMS).
o    £10.1m from the Wellcome Trust for basic science infrastructure and new clinical research facilities at the IMS, and to support joint working with the Sanger Institute.
o    £2.5m from the MRC for research into biomarkers for diabetes at the MRC Epidemiology Unit, University of Cambridge (Directed by Professor Nick Wareham and located at the Wellcome Trust-MRC IMS).
o    £1m from the MRC for a collaborative programme to investigate human fat metabolism led by MRC Human Nutrition Research (Directed by Professor Ann Prentice and based at the Elsie Widdowson Laboratory in Cambridge).

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genetic Signature Linked to Cancer Prognosis Identified
The results of the analysis of 8,161 tissue samples could in the future help clinicians decide how best to treat a patient as well as aid the development of new targeted treatments.
Monday, October 10, 2016
Potential Urine Test for CJD
Researchers at the Medical Research Council (MRC) Prion Unit at UCL have found that it may be possible to determine whether or not a person has sporadic Creutzfeldt-Jakob Disease (sCJD) by testing their urine for the presence of abnormal prion proteins.
Tuesday, October 04, 2016
Genes Essential to Life Discovered
Genes critical for life are discovered in humans and mice as part of large-scale phenotyping study.
Thursday, September 15, 2016
Gene Linked to Hearing Loss Identified
Researchers have identifed a gene associated with age-related hearing loss.
Monday, August 22, 2016
World's Most In-Depth Study to Detect Alzheimer's Disease
A multisite team will see the most thorough and vigorous testing for Alzheimer's ever performed on volunteers.
Monday, August 22, 2016
Discovery of Key Component of HIV Yields New Drug Target
Scientists from the MRC Laboratory of Molecular Biology in Cambridge and University College London have discovered an essential feature of HIV that the virus uses to infect cells whilst avoiding detection by the immune system. This discovery presents a new drug target and the opportunity to re-evaluate existing treatments for HIV to improve their efficacy.
Thursday, August 11, 2016
MRC Technology, Alzheimer’s Association Collaborate
MRC Technology (MRCT), an independent medical research charity based in London, and the Alzheimer’s Association in Chicago have entered into an agreement to review and monitor the Association’s grant-funded research portfolio.
Thursday, January 21, 2016
Study Shows Blocking Brain Inflammation Could Help Alzheimer's
The research was jointly funded by the Medical Research Council (MRC) and Alzheimer’s Research UK.
Saturday, January 09, 2016
A Fundamental Protection Mechanism Against Formalin In Mammals is Revealed
Formaldehyde, or formalin, is well known to all of us as a common chemical used in many industrial processes and also as a preservative, remarkably we also produce formaldehyde in our bodies.
Wednesday, September 30, 2015
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Wednesday, July 22, 2015
MRC, GSK and Five Leading UK Universities Collaborate
Collaboration to crack difficult disease areas.
Thursday, July 16, 2015
‘Mini Bile Ducts’ used to Discover New Drugs that could Prevent Liver Damage
An experimental cystic fibrosis drug has been shown to prevent the disease’s damage to the liver, thanks to a world-first where scientists grew mini bile ducts in the lab.
Tuesday, July 14, 2015
First RNAi Meiosis Screen Reveals Genes Essential to Generate Eggs
Screening techniques developed leading to the discovery of genes essential for meiosis in mammals.
Wednesday, July 08, 2015
Study Identifies New Way to Kill the Malaria Parasite
Scientists have discovered new ways in which the malaria parasite survives in the blood stream of its victims, a discovery that could pave the way to new treatments for the disease.
Tuesday, July 07, 2015
Making Vaccines More Effective In The Elderly
Compound shown to restore the immune system’s inbuilt memory.
Tuesday, November 11, 2014
Scientific News
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
ALS Study Reveals Role of RNA-Binding Proteins
The findings are a significant step forward in validating RNA-based therapy as a treatment for ALS.
New Compound Shows Promise in Treating Multiple Human Cancers
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of all cancers.
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
Lab-on-a-Chip to Help Detect Cancer
In this podcast, we speak to Gustavo Stolovitsky to learn about his career and the work he is doing at IBM Research.
Using CRISPR to Accelerate Search for HIV Cure
Gene-editing platform makes it easier to create HIV-resistant immune cells.
Nanomedicine Aims to Improve HIV Drug Therapies
New research aims to improve the administration and availability of drug therapies to HIV patients using nanotechnology.
Gene Editing Corrects Sickle Cell Mutation
Researchers demonstrate a potential pathway to developing gene-editing treatments for sickle cell disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos